<?xml version='1.0' encoding='utf-8'?>
<document id="25571290"><sentence text="A pharmacokinetic drug-drug interaction model of simvastatin and clarithromycin in humans."><entity charOffset="49-60" id="DDI-PubMed.25571290.s1.e0" text="simvastatin" /><entity charOffset="65-79" id="DDI-PubMed.25571290.s1.e1" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.25571290.s1.e0" e2="DDI-PubMed.25571290.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25571290.s1.e0" e2="DDI-PubMed.25571290.s1.e1" /></sentence><sentence text="Simvastatin is a HMG-CoA reductase Inhibitor and a substrate of CYP3A4"><entity charOffset="0-11" id="DDI-PubMed.25571290.s2.e0" text="Simvastatin" /></sentence><sentence text=" Clarithromycin is a commonly used macrolide antibiotics and a potent inhibitor of CYP3A4"><entity charOffset="1-15" id="DDI-PubMed.25571290.s3.e0" text="Clarithromycin" /></sentence><sentence text=" When co-administered with simvastatin, clarithromycin can significantly increase simvastatin plasma concentration levels, thereby, increase the risk of rhabdomyolysis"><entity charOffset="27-38" id="DDI-PubMed.25571290.s4.e0" text="simvastatin" /><entity charOffset="40-54" id="DDI-PubMed.25571290.s4.e1" text="clarithromycin" /><entity charOffset="82-93" id="DDI-PubMed.25571290.s4.e2" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.25571290.s4.e0" e2="DDI-PubMed.25571290.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25571290.s4.e0" e2="DDI-PubMed.25571290.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25571290.s4.e0" e2="DDI-PubMed.25571290.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25571290.s4.e1" e2="DDI-PubMed.25571290.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25571290.s4.e1" e2="DDI-PubMed.25571290.s4.e2" /></sentence><sentence text=" At present, pharmacokinetic data of the interaction between both drugs are available" /><sentence text=" However, they are being used for semi-quantitative application only, not for quantitative prediction" /><sentence text=" We aimed to develop a mathematical model describing a drug-drug interaction between simvastatin and clarithromycin in humans"><entity charOffset="85-96" id="DDI-PubMed.25571290.s7.e0" text="simvastatin" /><entity charOffset="101-115" id="DDI-PubMed.25571290.s7.e1" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.25571290.s7.e0" e2="DDI-PubMed.25571290.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25571290.s7.e0" e2="DDI-PubMed.25571290.s7.e1" /></sentence><sentence text="" /><sentence text="Selected pharmacokinetic interaction study was obtained from PubMed search" /><sentence text=" Concentration-time course data were subsequently extracted and used for model development" /><sentence text=" Compartmental pharmacokinetic interaction model was developed using Advanced Continuous Simulating Language Extreme (ACSLX), a FORTRAN language-based computer program" /><sentence text="" /><sentence text="The drug-drug interaction between simvastatin and clarithromycin was modeled simultaneously with a parent-metabolite model for clarithromycin and a one-compartment model for simvastatin linked to its active form, simvastatin hydroxy acid"><entity charOffset="34-45" id="DDI-PubMed.25571290.s13.e0" text="simvastatin" /><entity charOffset="50-64" id="DDI-PubMed.25571290.s13.e1" text="clarithromycin" /><entity charOffset="127-141" id="DDI-PubMed.25571290.s13.e2" text="clarithromycin" /><entity charOffset="174-185" id="DDI-PubMed.25571290.s13.e3" text="simvastatin" /><entity charOffset="213-237" id="DDI-PubMed.25571290.s13.e4" text="simvastatin hydroxy acid" /><pair ddi="false" e1="DDI-PubMed.25571290.s13.e0" e2="DDI-PubMed.25571290.s13.e0" /><pair ddi="false" e1="DDI-PubMed.25571290.s13.e0" e2="DDI-PubMed.25571290.s13.e1" /><pair ddi="false" e1="DDI-PubMed.25571290.s13.e0" e2="DDI-PubMed.25571290.s13.e2" /><pair ddi="false" e1="DDI-PubMed.25571290.s13.e0" e2="DDI-PubMed.25571290.s13.e3" /><pair ddi="false" e1="DDI-PubMed.25571290.s13.e0" e2="DDI-PubMed.25571290.s13.e4" /><pair ddi="false" e1="DDI-PubMed.25571290.s13.e1" e2="DDI-PubMed.25571290.s13.e1" /><pair ddi="false" e1="DDI-PubMed.25571290.s13.e1" e2="DDI-PubMed.25571290.s13.e2" /><pair ddi="false" e1="DDI-PubMed.25571290.s13.e1" e2="DDI-PubMed.25571290.s13.e3" /><pair ddi="false" e1="DDI-PubMed.25571290.s13.e1" e2="DDI-PubMed.25571290.s13.e4" /><pair ddi="false" e1="DDI-PubMed.25571290.s13.e2" e2="DDI-PubMed.25571290.s13.e2" /><pair ddi="false" e1="DDI-PubMed.25571290.s13.e2" e2="DDI-PubMed.25571290.s13.e3" /><pair ddi="false" e1="DDI-PubMed.25571290.s13.e2" e2="DDI-PubMed.25571290.s13.e4" /><pair ddi="false" e1="DDI-PubMed.25571290.s13.e3" e2="DDI-PubMed.25571290.s13.e3" /><pair ddi="false" e1="DDI-PubMed.25571290.s13.e3" e2="DDI-PubMed.25571290.s13.e4" /></sentence><sentence text=" The simulated simvastatin concentrations obtained from the final model displayed satisfactory goodness of fit to the data from the literature"><entity charOffset="15-26" id="DDI-PubMed.25571290.s14.e0" text="simvastatin" /></sentence><sentence text="" /><sentence text="Our model could successfully describe concentration-time course of simvastatin-clarithromycin interaction"><entity charOffset="67-78" id="DDI-PubMed.25571290.s16.e0" text="simvastatin" /><entity charOffset="79-93" id="DDI-PubMed.25571290.s16.e1" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.25571290.s16.e0" e2="DDI-PubMed.25571290.s16.e0" /><pair ddi="false" e1="DDI-PubMed.25571290.s16.e0" e2="DDI-PubMed.25571290.s16.e1" /></sentence><sentence text=" The resulting interaction model can be able to use for further development of a quantitative model predicting rhabdomyolysis occurrence in patients concurrently receiving simvastatin and clarithromycin"><entity charOffset="172-183" id="DDI-PubMed.25571290.s17.e0" text="simvastatin" /><entity charOffset="188-202" id="DDI-PubMed.25571290.s17.e1" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.25571290.s17.e0" e2="DDI-PubMed.25571290.s17.e0" /><pair ddi="false" e1="DDI-PubMed.25571290.s17.e0" e2="DDI-PubMed.25571290.s17.e1" /></sentence><sentence text="" /></document>